Generic Name and Formulations:
Gemifloxacin mesylate 320mg; scored tabs.
Merus Labs International, Inc.
Indications for FACTIVE:
Susceptible infections including acute bacterial exacerbation of chronic bronchitis (ABECB) and mild-to-moderate community-acquired pneumonia. For ABECB: reserve for those who have no alternative treatment options.
≥18yrs: Swallow whole. Take with full glass of water. 320mg once daily. ABECB: treat for 5 days. Community-acquired pneumonia: treat for 5 or 7 days (based on susceptible bacteria; see full labeling). Renal impairment and dialysis: CrCl ≤40mL/min: 160mg every 24hrs.
<18yrs: not established.
Increased risk of disabling and potentially irreversible adverse reactions (including tendinitis/tendon rupture [esp. in patients >60yrs, or those with kidney, heart or lung transplants], peripheral neuropathy, or CNS effects); discontinue immediately if signs/symptoms occur. Epilepsy or predisposition to convulsions. History of myasthenia gravis; avoid. History of QT prolongation, ventricular arrhythmias, proarrhythmic conditions (eg, bradycardia, acute myocardial ischemia), electrolyte disorders (eg, hypokalemia, or hypomagnesemia); avoid. Do not exceed recommended dose and length of therapy esp. in renal or hepatic impairment; may increase QT prolongation. Discontinue at 1st sign of a skin rash, jaundice, or any other hypersensitivity. Maintain adequate hydration. Avoid excessive sun or UV light. Elderly. Pregnancy (Cat.C), nursing mothers: not recommended.
Avoid drugs that prolong QTc interval (eg, Class IA or Class III antiarrhythmics, erythromycin, antipsychotics, tricyclics). Separate dosing of magnesium- or aluminum-containing antacids and didanosine, sucralfate, iron, zinc, other metal cations (do not take within 3hrs before or 2hrs after gemifloxacin). Potentiated by probenecid. Increased risk of tendinitis/tendon rupture with corticosteroids. Monitor warfarin.
Diarrhea, rash, nausea, urticaria, headache, abdominal pain, vomiting, dizziness, elevated liver enzymes; photosensitivity (discontinue if occurs), tendinitis/tendon rupture, torsades de pointes, peripheral neuropathy, convulsions, C. difficile-associated diarrhea.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Clostridium Difficile Infection in Patients With Cancer — In the Clinic
- Can A Consortium of Hospitals Help To Reduce Drug Prices?
- NSCLC: Stratifying Patients With Complex EGFR Mutations
- Targeted and Immunotherapies for Metastatic Renal Cell Carcinoma
- FDA Approves Front-Line Brentuximab Vedotin Plus Chemotherapy for Hodgkin Lymphoma
- Everolimus Plus Letrozole: An Effective First-Line Therapy for Advanced Breast Cancer
- FDA Approves Nilotinib for Pediatric Patients With CML
- Nicotinamide and Cancer
- Nivolumab Plus Ipilimumab Improves Overall Survival, ORR in Renal Cell Carcinoma
- Encorafenib, Binimetinib May Be Effective in BRAF-Mutant Melanoma